

INNOVATION Kyoto 2016 LSP Completes Investment in Series B of Chordia Therapeutics Inc.

- Chordia Therapeutics Inc., an oncology research and development company based in Kanagawa, Japan, raises total of approximately 3.0B JPY (27M USD) in the Series B financing.

Kyoto, Japan, March 29, 2019 – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “KYOTO-iCAP”), today announced it has concluded total of approximately 3.0B JPY investment in Chordia Therapeutics Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake; “Chordia”), developing multiple anti-cancer drug candidates.

The financing was co-led by JAFCO and KYOTO-iCAP, with participation from Shinsei Capital Partners, Mitsubishi UFJ Capital, SMBC Venture Capital and Nippon Venture Capital. KYOTO-iCAP hopes that this financing will accelerate the development of Chordia’s pipeline assets and they will benefit cancer patients and their families in the near future.

For more information, visit in <http://www.chordiatherapeutics.com/eng/> or contact info@chordiatherapeutics.com

About Kyoto University Innovation Capital Co., Ltd. (“Kyoto iCAP”)

Kyoto iCAP is a wholly owned subsidiary of Kyoto University established in December 2014. Its purpose is to provide investment and support to companies founded by researchers belonging to Kyoto University (including spin-offs from joint research companies) for commercializing knowledge (including research results, technology, etc.). The KYOTO-iCAP 1st Fund was created from a 16billion-yen capital contribution from Kyoto University and private financial institutions, in January 2016. KYOTO-iCAP is a general partner of the Fund. The fund management period is 15 years, that enables KYOTO-iCAP to support Kyoto University-originated ventures with long-term and to provide equity from the seed stage to practical application. The university is one of the top research institutions in Asia.

Overview of Chordia Therapeutics Inc.

Date established: 10/12/2017

Scope of business: Research and development of new anti-cancer drugs

Location: Fujisawa City, Kanagawa Prefecture

CEO: Hiroshi Miyake



【Contact Information】

Kyoto University Innovation Capital Co., Ltd. 36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317

Japan Kyoto University International Science Innovation Building, East Building, 4th Floor

Head of Media Relations: Osami Kono

Tel: +81-(0)75-753-5303, Fax: +81-(0)75-753-7592

Email: info@kyoto-unicap.co.jp